dc.contributor.author | Langat, R | |
dc.contributor.author | Omosa-Manyoni, G | |
dc.contributor.author | Farah, B | |
dc.date.accessioned | 2014-08-14T08:44:48Z | |
dc.date.available | 2014-08-14T08:44:48Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Langat,R.,Omosa-Manyoni, G.,Farah,B.,2013.Selection and Optimization of a Mucosal Sampling Method for Application in Phase 1 Clinical Trials. | en_US |
dc.identifier.uri | http://hdl.handle.net/11295/73746 | |
dc.description.abstract | Background: An efficacious preventive HIV vaccine will likely
require induction of immune responses at mucosal surfaces.
One approach is to deliver vaccines intra-nasally. A pilot
study was performed in Rwanda and Kenya to determine if
anti-HIV antibodies could be detected in nasal secretions
collected from the nasal cavity (NC), naso-pharynx (NP) and
oral secretions.
Methods: Nasal samples were collected using FloQ Swabs from
35 HIV-seropositive and 35 HIV-seronegative volunteers. Saliva
was collected from parotid glands using Salimetrics Oral Swabs,
oral fluid (transudate) was collected into Falcon tubes. Eluted
samples were tested for gp140 Env (Clade A UG37) and Gag p24
(Clade B LAI) IgG and IgA antibodies.
Results: Volunteers indicated that the NC collection was preferable
to the deeper NP sample, suggesting that NC sampling may
result in greater compliance with repeated sampling. Anti-HIV
antibodies were detected in nasal secretions of 100% of HIVseropositive
samples with IgG expressed at a higher level than
IgA. Anti-gp140 IgG and anti-p24 IgG were detected in 100% and
93.4% of nasal samples, respectively. IgA anti-gp140 and anti-p24
IgA were detected in 94% and 88.5% of nasal samples, respectively.
No significant differences were detected between NC and
NP samples in magnitude or quantity. All nasal samples from
HIV-seronegative volunteers were negative for IgG and IgA antigp140/
p24 except for 4 Rwandan volunteers with low levels of
IgA anti-p24.
Conclusion: NP sampling appeared to have little benefit over NC
sampling, and HIV antibodies were detected in all HIV-seropositive
individuals. NC sampling may provide a unique and
tolerable method to collect antibodies in an HIV vaccine trial
following intranasal vaccination. | en_US |
dc.language.iso | en | en_US |
dc.publisher | University Of Nairobi | en_US |
dc.title | Selection and Optimization of a Mucosal Sampling Method for Application in Phase 1 Clinical Trials | en_US |
dc.type | Article | en_US |
dc.type.material | en | en_US |